DNA/RNA heteroduplex oligonucleotide technology for regulating lymphocytes in vivo.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
22 12 2021
Historique:
received: 28 03 2020
accepted: 19 10 2021
entrez: 23 12 2021
pubmed: 24 12 2021
medline: 12 1 2022
Statut: epublish

Résumé

Manipulating lymphocyte functions with gene silencing approaches is promising for treating autoimmunity, inflammation, and cancer. Although oligonucleotide therapy has been proven to be successful in treating several conditions, efficient in vivo delivery of oligonucleotide to lymphocyte populations remains a challenge. Here, we demonstrate that intravenous injection of a heteroduplex oligonucleotide (HDO), comprised of an antisense oligonucleotide (ASO) and its complementary RNA conjugated to α-tocopherol, silences lymphocyte endogenous gene expression with higher potency, efficacy, and longer retention time than ASOs. Importantly, reduction of Itga4 by HDO ameliorates symptoms in both adoptive transfer and active experimental autoimmune encephalomyelitis models. Our findings reveal the advantages of HDO with enhanced gene knockdown effect and different delivery mechanisms compared with ASO. Thus, regulation of lymphocyte functions by HDO is a potential therapeutic option for immune-mediated diseases.

Identifiants

pubmed: 34937876
doi: 10.1038/s41467-021-26902-8
pii: 10.1038/s41467-021-26902-8
pmc: PMC8695577
doi:

Substances chimiques

Malat1 long non-coding RNA, mouse 0
Nucleic Acid Heteroduplexes 0
Oligonucleotides 0
RNA, Long Noncoding 0
RNA, Messenger 0
Integrin alpha4 143198-26-9
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7344

Informations de copyright

© 2021. The Author(s).

Références

Tintore, M., Vidal-Jordana, A. & Sastre-Garriga, J. Treatment of multiple sclerosis - success from bench to bedside. Nat. Rev. Neurol. 15, 53–58 (2019).
pubmed: 30315270 doi: 10.1038/s41582-018-0082-z
Carter, P. J. & Lazar, G. A. Next generation antibody drugs: pursuit of the ‘high-hanging fruit’. Nat. Rev. Drug Discov. 17, 197–223 (2018).
pubmed: 29192287 doi: 10.1038/nrd.2017.227
Shen, X. & Corey, D. R. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 46, 1584–1600 (2018).
pubmed: 29240946 doi: 10.1093/nar/gkx1239
Mantei, A. et al. siRNA stabilization prolongs gene knockdown in primary T lymphocytes. Eur. J. Immunol. 38, 2616–2625 (2008).
pubmed: 18792414 doi: 10.1002/eji.200738075
Zhao, Y. et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13, 151–159 (2006).
pubmed: 16140584 doi: 10.1016/j.ymthe.2005.07.688
Ebert, O. et al. Lymphocyte apoptosis: induction by gene transfer techniques. Gene Ther. 4, 296–302 (1997).
pubmed: 9176514 doi: 10.1038/sj.gt.3300394
Freeley, M. & Long, A. The two hit hypothesis: an improved method for siRNA-mediated gene silencing in stimulated primary human T cells. J. Immunol. Methods 396, 116–127 (2013).
pubmed: 23988722 doi: 10.1016/j.jim.2013.08.005
Fazil, M. H. et al. GapmeR cellular internalization by macropinocytosis induces sequence-specific gene silencing in human primary T-cells. Sci. Rep. 6, 37721 (2016).
pubmed: 27883055 pmcid: 5121623 doi: 10.1038/srep37721
Ramishetti, S. et al. Systemic gene silencing in primary T lymphocytes using targeted lipid nanoparticles. ACS Nano 9, 6706–6716 (2015).
pubmed: 26042619 doi: 10.1021/acsnano.5b02796
Gamrad, L. et al. Efficient nucleic acid delivery to murine regulatory T cells by gold nanoparticle conjugates. Sci. Rep. 6, 28709 (2016).
pubmed: 27381215 pmcid: 4933883 doi: 10.1038/srep28709
Wheeler, L. A. et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J. Clin. Investig. 121, 2401–2412 (2011).
pubmed: 21576818 pmcid: 3104760 doi: 10.1172/JCI45876
Nishina, K. et al. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat. Commun. 6, 7969 (2015).
pubmed: 26258894 pmcid: 4918363 doi: 10.1038/ncomms8969
Kuwahara, H. et al. Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo. Sci. Rep. 8, 4377 (2018).
pubmed: 29531265 pmcid: 5847588 doi: 10.1038/s41598-018-22577-2
Rigotti, A. Absorption, transport, and tissue delivery of vitamin E. Mol. Asp. Med. 28, 423–436 (2007).
doi: 10.1016/j.mam.2007.01.002
Marko, M. G. et al. Age-associated decline in effective immune synapse formation of CD4(+) T cells is reversed by vitamin E supplementation. J. Immunol. 178, 1443–1449 (2007).
pubmed: 17237392 doi: 10.4049/jimmunol.178.3.1443
Roy, R. M., Petrella, M. & Ross, W. M. Modification of mitogen-induced proliferation of murine splenic lymphocytes by in vitro tocopherol. Immunopharmacol. Immunotoxicol. 13, 531–550 (1991).
pubmed: 1774435 doi: 10.3109/08923979109019721
Sridharan, K. & Gogtay, N. J. Therapeutic nucleic acids: current clinical status. Br. J. Clin. Pharmacol. 82, 659–672 (2016).
pubmed: 27111518 pmcid: 5338117 doi: 10.1111/bcp.12987
Hemler, M. E., Elices, M. J., Parker, C. & Takada, Y. Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions. Immunol. Rev. 114, 45–65 (1990).
pubmed: 2142475 doi: 10.1111/j.1600-065X.1990.tb00561.x
Hung, G. et al. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther. 23, 369–378 (2013).
pubmed: 24161045 doi: 10.1089/nat.2013.0443
Pandey, S. K. et al. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J. Pharmacol. Exp. Ther. 355, 329–340 (2015).
pubmed: 26330536 pmcid: 4613955 doi: 10.1124/jpet.115.226969
Carrell, S. T. et al. Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice. Hum. Mol. Genet. 25, 4328–4338 (2016).
pubmed: 27522499 pmcid: 5291200 doi: 10.1093/hmg/ddw266
Juliano, R. L., Ming, X., Carver, K. & Laing, B. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther. 24, 101–113 (2014).
pubmed: 24383421 pmcid: 3962645 doi: 10.1089/nat.2013.0463
Juliano, R. L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 44, 6518–6548 (2016).
pubmed: 27084936 pmcid: 5001581 doi: 10.1093/nar/gkw236
Qian, J. et al. Intracellular trafficking of vitamin E in hepatocytes: the role of tocopherol transfer protein. J. Lipid Res. 46, 2072–2082 (2005).
pubmed: 16024914 doi: 10.1194/jlr.M500143-JLR200
Fretz, M. et al. Effects of Na
pubmed: 16971016 doi: 10.1016/j.jconrel.2006.07.009
Chang, C. C., Wu, M. & Yuan, F. Role of specific endocytic pathways in electrotransfection of cells. Mol. Ther. Methods Clin. Dev. 1, 14058 (2014).
pubmed: 26052524 pmcid: 4448742 doi: 10.1038/mtm.2014.58
Rasmussen, I. & Vilhardt, F. Macropinocytosis is the entry mechanism of amphotropic murine leukemia virus. J. Virol. 89, 1851–1866 (2015).
pubmed: 25428868 doi: 10.1128/JVI.02343-14
Koivusalo, M. et al. Amiloride inhibits macropinocytosis by lowering submembranous pH and preventing Rac1 and Cdc42 signaling. J. Cell Biol. 188, 547–563 (2010).
pubmed: 20156964 pmcid: 2828922 doi: 10.1083/jcb.200908086
Rejman, J., Bragonzi, A. & Conese, M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol. Ther. 12, 468–474 (2005).
pubmed: 15963763 doi: 10.1016/j.ymthe.2005.03.038
Daniel, J. A. et al. Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis. Traffic 16, 635–654 (2015).
pubmed: 25693808 doi: 10.1111/tra.12272
Macia, E. et al. Dynasore, a cell-permeable inhibitor of dynamin. Dev. Cell 10, 839–850 (2006).
pubmed: 16740485 doi: 10.1016/j.devcel.2006.04.002
Marella, M., Lehmann, S., Grassi, J. & Chabry, J. Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J. Biol. Chem. 277, 25457–25464 (2002).
pubmed: 11994310 doi: 10.1074/jbc.M203248200
Orlandi, P. A. & Fishman, P. H. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J. Cell Biol. 141, 905–915 (1998).
pubmed: 9585410 pmcid: 2132770 doi: 10.1083/jcb.141.4.905
Beletskii, A. et al. High-throughput phagocytosis assay utilizing a pH-sensitive fluorescent dye. Biotechniques 39, 894–897 (2005).
pubmed: 16382909 doi: 10.2144/000112001
Honarpisheh, M. et al. Phagocytosis of environmental or metabolic crystalline particles induces cytotoxicity by triggering necroptosis across a broad range of particle size and shape. Sci. Rep. 7, 15523 (2017).
pubmed: 29138474 pmcid: 5686194 doi: 10.1038/s41598-017-15804-9
Reilley, M. J. et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J. Immunother. Cancer 6, 119 (2018).
pubmed: 30446007 pmcid: 6240242 doi: 10.1186/s40425-018-0436-5
Polman, C. H. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354, 899–910 (2006).
pubmed: 16510744 doi: 10.1056/NEJMoa044397
Wysocki, C. A., Panoskaltsis-Mortari, A., Blazar, B. R. & Serody, J. S. Leukocyte migration and graft-versus-host disease. Blood 105, 4191–4199 (2005).
pubmed: 15701715 pmcid: 1895033 doi: 10.1182/blood-2004-12-4726
Alahmari, B. et al. Selective targeting of α4β1 integrin attenuates murine graft versus host disease. Leukemia 34, 3100–3104 (2020).
pubmed: 32152466 pmcid: 7483240 doi: 10.1038/s41375-020-0786-0
Choi, J. et al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32, 2483–2494 (2018).
pubmed: 29691471 pmcid: 6168427 doi: 10.1038/s41375-018-0123-z
McKinlay, C. J., Benner, N. L., Haabeth, O. A., Waymouth, R. M. & Wender, P. A. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters. Proc. Natl Acad. Sci. USA 115, E5859–E5866 (2018).
pubmed: 29891683 pmcid: 6042134 doi: 10.1073/pnas.1805358115
Mizrahy, S., Hazan-Halevy, I., Dammes, N., Landesman-Milo, D. & Peer, D. Current progress in non-viral RNAi-based delivery strategies to lymphocytes. Mol. Ther. 25, 1491–1500 (2017).
pubmed: 28392163 pmcid: 5498814 doi: 10.1016/j.ymthe.2017.03.001
Kabelitz, D. Expression and function of Toll-like receptors in T lymphocytes. Curr. Opin. Immunol. 19, 39–45 (2007).
pubmed: 17129718 doi: 10.1016/j.coi.2006.11.007
Petterson, T., Månsson, A., Riesbeck, K. & Cardell, L. O. Nucleotide-binding and oligomerization domain-like receptors and retinoic acid inducible gene-like receptors in human tonsillar T lymphocytes. Immunology 133, 84–93 (2011).
pubmed: 21342182 pmcid: 3088970 doi: 10.1111/j.1365-2567.2011.03414.x
Gulen, M. F. et al. Signalling strength determines proapoptotic functions of STING. Nat. Commun. 8, 427–427 (2017).
pubmed: 28874664 pmcid: 5585373 doi: 10.1038/s41467-017-00573-w
Ebert, O. et al. TNF-alpha secretion and apoptosis of lymphocytes mediated by gene transfer. Cytokines Cell Mol. Ther. 5, 165–173 (1999).
pubmed: 10641575
Ramishetti, S. & Peer, D. Engineering lymphocytes with RNAi. Adv. Drug Deliv. Rev. 141, 55–66 (2018).
Kedmi, R. et al. A modular platform for targeted RNAi therapeutics. Nat. Nanotechnol. 13, 214–219 (2018).
pubmed: 29379205 doi: 10.1038/s41565-017-0043-5
Herrmann, A. et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J. Clin. Investig. 124, 2977–2987 (2014).
pubmed: 24892807 pmcid: 4071407 doi: 10.1172/JCI73174
Song, E. et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709–717 (2005).
pubmed: 15908939 doi: 10.1038/nbt1101
Peer, D., Zhu, P., Carman, C. V., Lieberman, J. & Shimaoka, M. Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1. Proc. Natl Acad. Sci. USA 104, 4095–4100 (2007).
pubmed: 17360483 pmcid: 1820714 doi: 10.1073/pnas.0608491104
Kumar, P. et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134, 577–586 (2008).
pubmed: 18691745 pmcid: 2943428 doi: 10.1016/j.cell.2008.06.034
Khvorova, A. & Watts, J. K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017).
pubmed: 28244990 pmcid: 5517098 doi: 10.1038/nbt.3765
Myers, K. J. et al. Antisense oligonucleotide blockade of alpha 4 integrin prevents and reverses clinical symptoms in murine experimental autoimmune encephalomyelitis. J. Neuroimmunol. 160, 12–24 (2005).
pubmed: 15710453 doi: 10.1016/j.jneuroim.2004.10.029
Duchartre, Y. et al. Effects of CD49d-targeted antisense-oligonucleotide on alpha4 integrin expression and function of acute lymphoblastic leukemia cells: results of in vitro and in vivo studies. PLoS ONE 12, e0187684 (2017).
pubmed: 29117236 pmcid: 5678723 doi: 10.1371/journal.pone.0187684
Thomas, S. N., Rohner, N. A. & Edwards, E. E. Implications of lymphatic transport to lymph nodes in immunity and immunotherapy. Annu. Rev. Biomed. Eng. 18, 207–233 (2016).
pubmed: 26928210 pmcid: 5518935 doi: 10.1146/annurev-bioeng-101515-014413
de Pablo, R., Monserrat, J., Prieto, A. & Alvarez-Mon, M. Role of circulating lymphocytes in patients with sepsis. Biomed. Res. Int. 2014, 671087 (2014).
pubmed: 25302303 pmcid: 4163419 doi: 10.1155/2014/671087
Adolfsson, O., Huber, B. T. & Meydani, S. N. Vitamin E-enhanced IL-2 production in old mice: naive but not memory T cells show increased cell division cycling and IL-2-producing capacity. J. Immunol. 167, 3809–3817 (2001).
pubmed: 11564798 doi: 10.4049/jimmunol.167.7.3809
Marko, M. G. et al. Vitamin E reverses impaired linker for activation of T cells activation in T cells from aged C57BL/6 mice. J. Nutr. 139, 1192–1197 (2009).
pubmed: 19403707 pmcid: 2714384 doi: 10.3945/jn.108.103416
Li-Weber, M. et al. Vitamin E inhibits CD95 ligand expression and protects T cells from activation-induced cell death. J. Clin. Investig. 110, 681–690 (2002).
pubmed: 12208869 pmcid: 151103 doi: 10.1172/JCI0215073
Kappus, H. & Diplock, A. T. Tolerance and safety of vitamin E: a toxicological position report. Free Radic. Biol. Med. 13, 55–74 (1992).
pubmed: 1628854 doi: 10.1016/0891-5849(92)90166-E
Rajagopalan, A., Berezhnoy, A., Schrand, B., Puplampu-Dove, Y. & Gilboa, E. Aptamer-targeted attenuation of IL-2 signaling in CD8(+) T cells enhances antitumor immunity. Mol. Ther. 25, 54–61 (2017).
pubmed: 28129128 pmcid: 5363184 doi: 10.1016/j.ymthe.2016.10.021
Hogg, N., Patzak, I. & Willenbrock, F. The insider’s guide to leukocyte integrin signalling and function. Nat. Rev. Immunol. 11, 416–426 (2011).
pubmed: 21597477 doi: 10.1038/nri2986
Wang, S. et al. Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res. 46, 3579–3594 (2018).
pubmed: 29514240 pmcid: 5909429 doi: 10.1093/nar/gky145
Miller, C. M. et al. Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res. 44, 2782–2794 (2016).
pubmed: 26908652 pmcid: 4824115 doi: 10.1093/nar/gkw112
Alam, M. R. et al. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res. 36, 2764–2776 (2008).
pubmed: 18367474 pmcid: 2377441 doi: 10.1093/nar/gkn115
Ming, X. et al. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor. Nucleic Acids Res. 38, 6567–6576 (2010).
pubmed: 20551131 pmcid: 2965246 doi: 10.1093/nar/gkq534
Geary, R. S., Norris, D., Yu, R. & Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51 (2015).
pubmed: 25666165 doi: 10.1016/j.addr.2015.01.008
Lai, H. Y., Chou, T. Y., Tzeng, C. H. & Lee, O. K. Cytokine profiles in various graft-versus-host disease target organs following hematopoietic stem cell transplantation. Cell Transplant. 21, 2033–2045 (2012).
pubmed: 22840591 doi: 10.3727/096368912X653110
Fruman, D. A., Pai, S. Y., Burakoff, S. J. & Bierer, B. E. Characterization of a mutant calcineurin A alpha gene expressed by EL4 lymphoma cells. Mol. Cell Biol. 15, 3857–3863 (1995).
pubmed: 7791792 pmcid: 230625 doi: 10.1128/MCB.15.7.3857
Ku, H. & Meier, K. E. Phosphorylation of paxillin via the ERK mitogen-activated protein kinase cascade in EL4 thymoma cells. J. Biol. Chem. 275, 11333–11340 (2000).
pubmed: 10753946 doi: 10.1074/jbc.275.15.11333
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
pubmed: 22743772 doi: 10.1038/nmeth.2019

Auteurs

Masaki Ohyagi (M)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan.

Tetsuya Nagata (T)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. t-naga.nuro@tmd.ac.jp.
Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan. t-naga.nuro@tmd.ac.jp.

Kensuke Ihara (K)

Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.

Kie Yoshida-Tanaka (K)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan.

Rieko Nishi (R)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan.

Haruka Miyata (H)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan.

Aya Abe (A)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan.

Yo Mabuchi (Y)

Department of Biochemistry and Biophysics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Chihiro Akazawa (C)

Department of Biochemistry and Biophysics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Takanori Yokota (T)

Department of Neurology and Neurological Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. tak-yokota.nuro@tmd.ac.jp.
Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan. tak-yokota.nuro@tmd.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH